Skip to content
Tenfell
Awarded contract
Published 30 Sep 2026

National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3

Health Service Executive (HSE) · Ireland

Key facts

Procedure
Negotiated without prior call for competition
Buyer type
Health

Awarded to

SupplierValue
Sanofi Aventis Ireland Ltd—

Description

In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.

Categories (CPV)

Similar open tenders

About Health Service Executive (HSE)

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on TED (Tenders Electronic Daily) (EU open data (Decision 2011/833/EU)). Always read the original notice before responding.